AlphAIalphai — Financial news for AI agents
rttnews.comAUG 252 min read$BCRX

BioCryst Wins Japan Approval For ORLADEYO In Pediatric HAE

BioCryst Pharmaceuticals (BCRX) received Japanese approval for ORLADEYO in pediatric HAE patients aged 2 to under 12. This is the first oral prophylactic therapy for children in Japan, supported by APeX-P trial data. BCRX stock closed at $9.68, up 1.36%, and is trading at $9.72 in pre-market.

Original reporting
rttnews.com
Published Aug 25, 2026, 12:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 12:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefRegulation
Primary signal
$BCRX
Bullish
high confidence
Mentioned
$BCRX
Relevance
8/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$BCRXBullishHigh
01

Why it matters

The approval could drive incremental sales and improve the company's growth trajectory, especially as it expands in Asia.

02

Market read

Regulatory clearance adds a new market for BioCryst, likely supporting its share price and influencing biotech peers.

03

What to watch

Potential competition from emerging gene‑therapy approaches for HAE.

Relevance 8/10Novelty 9/10Timing: pre-market today

Background

BioCryst announced its first pediatric oral prophylactic approval in Japan, following adult approval in 2021.

Company-level read

Ticker impact

$BCRXBullishHigh confidence
Context

Japan's health ministry approved ORLADEYO for pediatric HAE, a first oral prophylactic for children in that market.

Expected impact

Potential upside of 5‑10% over the next weeks as launch proceeds.

Evidence & confidence

Approval opens a new revenue stream; biotech peers typically rally on similar foreign clearances.

Market effects

Sector

Strengthens outlook for rare‑disease therapeutics and oral biologics in Japan.

Regional

May lift other biotech stocks with Japan pipelines.

Global

Adds to global momentum for ORLADEYO, supporting broader biotech sentiment.

Counterpoint

What could challenge this read

If pricing or reimbursement issues delay launch, the rally could be muted.

Key entities

  • Company
    BioCryst Pharmaceuticals Inc.

    Developer of ORLADEYO, a kallikrein inhibitor for HAE.

  • Regulator
    Japan Ministry of Health, Labor and Welfare

    Granted the pediatric indication approval.

  • Partner
    OrphanPacific, Inc.

    Local marketing partner for ORLADEYO in Japan.

Read at source← All news

Related articles

AUG 28
$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

finanznachrichten.de3 min
AUG 28
$BCRXMed

BioCryst is profitable. Now it wants to buy more rare disease drugs

BioCryst Pharmaceuticals, with a market cap under $5B, reported profitability and plans to expand through acquisitions in the rare disease space. Its FDA-approved drug Orladeyo generated over $2B in sales, with $645M forecasted for 2023. CEO Charlie Gayer aims to leverage the company's financial stability to acquire early-stage assets, targeting smaller peak sales potentials.

cnbc.com3 min
AUG 12
$BCRXMedAI 8/10

BioCryst (BCRX) Q2 2026 Earnings Call Transcript

BioCryst (BCRX) discussed its Q2 2026 earnings call, citing ORLADEYO revenue of $158.2M, up 10% year-on-year, and total revenue up 45% excluding the European divestiture. Paid therapy rate rose to 84% from 83% a year earlier. The company said it completed enrollment of the ALPHA-ORBIT pivotal study for navenibart, with top-line data expected in Q3 2027, and reported $113.2M non-GAAP operating profit and $350M+ cash.

yahoo.com7 min
AUG 5
$BCRXMed

BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

BioCryst Pharmaceuticals reported Q2 2026 results driven by ORLADEYO capsule demand, with total revenue up 45% YoY excluding divested European operations. Management said it ended internal drug discovery and closed its Birmingham unit. Full-year 2026 ORLADEYO guidance remains $625M to $645M. Cash and investments were over $350M.

yahoo.com6 min
AUG 5
$BCRXMed

BIOCRYST PHARMACEUTICALS INC (BCRX): Results of Operations and Financial Condition

BIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO reve

SEC EDGAR 8-K6 min
JUL 2
$VRTXMed

Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal

Biotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).

rttnews.com7 min